化疗放疗后nacVI-RADS对肌层浸润性膀胱癌病理完全缓解的诊断性能
该回顾性研究纳入73例接受顺铂为基础化疗放疗后行膀胱切除术的肌层浸润性膀胱癌患者,两位放射科医生独立评估化疗放疗后nacVI-RADS评分。nacVI-RADS<3与病理完全缓解相关,诊断敏感度78%-80%、特异度52%-59%,读者间一致性优秀(κ=0.845)。
要点
- 化疗放疗后nacVI-RADS<3提示病理完全缓解可能性较高。
- 以nacVI-RADS<3判断病理完全缓解的敏感度约78%-80%,特异度约52%-59%。
- 两位读者间一致性优秀(κ=0.845),评分可重复性好。
核心结论
- 化疗放疗后nacVI-RADS<3与肌层浸润性膀胱癌病理完全缓解相关,诊断性能中等,读者间一致性优秀。
研究设计与样本
- 回顾性研究纳入73例非转移性cT2-4aN0-2M0膀胱癌患者,2009至2024年接受顺铂为基础化疗放疗后行根治性或部分膀胱切除术。
- 两位放射科医生独立在MRI上分配化疗放疗后nacVI-RADS评分,主要分析将评分二分为<3和≥3。
- 参考标准为膀胱病理完全缓解,定义为病理评估ypT0。
诊断标准与关键数值
- nacVI-RADS<3判断病理完全缓解的敏感度和特异度:读者1为78%和59%,读者2为80%和52%。
- nacVI-RADS<3组病理完全缓解率高于≥3组:读者1为77%对39%(p=0.002),读者2为74%对39%(p=0.008)。
- 读者间一致性优秀,κ=0.845(95%CI 0.687-0.962)。
临床应用与阅片要点
- 化疗放疗后nacVI-RADS<3可作为提示病理完全缓解的补充信息,但特异度中等,需结合临床综合判断。
局限性
- 回顾性研究设计。
- 单中心研究,样本量73例。
- 结论需更大规模前瞻性多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate whether post-chemoradiotherapy neoadjuvant chemotherapy Vesical Imaging-Reporting and Data System (nacVI-RADS) is associated with pathological complete response (pCR), and to assess its diagnostic performance and inter-reader agreement in patients with muscle-invasive bladder cancer (MIBC).
MATERIALS AND METHODS: This retrospective study included 73 patients with non-metastatic cT2-4aN0-2 M0 bladder cancer who underwent cisplatin-based chemoradiotherapy followed by radical or partial cystectomy between 2009 and 2024. Two radiologists independently assigned post-chemoradiotherapy nacVI-RADS scores on MRI. For the primary diagnostic analysis, scores were dichotomized as < 3 and ≥ 3. The reference standard was bladder pCR, defined as ypT0 on pathological assessment.
RESULTS: pCR was achieved in 46 of 73 patients (63%). The pCR rate was higher among patients with nacVI-RADS < 3 than among those with nacVI-RADS ≥ 3 for both readers (reader 1: 77% vs. 39%, p = 0.002; reader 2: 74% vs. 39%, p = 0.008). The sensitivity and specificity of nacVI-RADS < 3 for identifying pCR were 78% and 59% for reader 1 and 80% and 52% for reader 2, respectively. Inter-reader agreement was excellent (κ = 0.845; 95% CI, 0.687-0.962).
CONCLUSION: Post-chemoradiotherapy nacVI-RADS < 3 was associated with pCR and showed moderate diagnostic performance with excellent inter-reader agreement in patients with MIBC. Post-chemoradiotherapy nacVI-RADS may provide useful complementary information for response assessment. Larger prospective multicenter studies are warranted to validate these findings.
引用
- Fukui K, Kobayashi M, Yoshida S, et al. Diagnostic performance of post-chemoradiotherapy nacVI-RADS for identifying pathological complete response in muscle-invasive bladder cancer. Eur J Radiol. 2026. PMID: 42880152. doi:10.1016/j.ejrad.2026.113292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。